लोफेक्सिडिन के इंटरैक्शन

• Effects on Driving and Operating Machinery: Patients receiving • alprazolam XR should be cautioned against operating machinery or driving a motor vehicle, as well as avoiding concomitant use of alcohol and other central nervous system (CNS) depressant drugs. (अल्प्राज़ोलम लेबल, चेतावनियां और सावधानियां)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with azelastine hydrochloride and fluticasone propionate nasal spray because further decreased alertness and impairment of CNS performance may occur. (एज़ेलास्टिन और फ्लुटिकासोन लेबल, चेतावनियां और सावधानियां)

…of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (एप्टिफिबाटाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

…Lipid-modifying Agents: lomitapide, lovastatin, simvastatin Phosphodiesterase-5 (PDE-5) Inhibitor: sildenafil when administered as REVATIO ® for the treatment of pulmonary arterial hypertension Sedative/hypnotics: triazolam, orally administered midazolam Coadministration of GENVOYA is contraindicated with drugs that: Are highly dependent on CYP3A for clearance and for which… (एल्विटेग्राविर, कोबिसिस्टैट, एमट्रिसिटाबिन और टेनोफोविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (एस्ज़ोपिक्लोन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

• Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (ओलोपाटाडीन लेबल, चेतावनियां और सावधानियां)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (ओलोपाटाडीन और मोमेटासोन लेबल, चेतावनियां और सावधानियां)

Avoid concurrent use of Carbinoxamine Maleate Extended-Release Oral Suspension with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur. (कार्बिनोक्सामिन लेबल, चेतावनियां और सावधानियां)

This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. (कीटोकोनाज़ोल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Benzodiazepines, Opioid Analgesics, or other CNS Depressants : Concomitant use may result in profound sedation, respiratory depression, coma, or death. (केटामिन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (क्लोज़ापिन लेबल, बॉक्स्ड चेतावनी)

Avoid use with other central nervous system (CNS) depressants ( 5.3 ) (क्लोनिडिन लेबल, चेतावनियां और सावधानियां)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (ज़ेलेप्लॉन लेबल, चेतावनियां)

The use of Zolpidem Tartrate with other sedative-hypnotics (including other zolpidem products) at bedtime or the middle of the night is not recommended. (ज़ोल्पिडेम लेबल, चेतावनियां और सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

…coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (टैडालाफिल लेबल, चेतावनियां और सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

• Effects on Driving and Operating Heavy Machinery : Patients receiving triazolam should be cautioned against driving or operating heavy machinery, as well as avoiding concomitant use with alcohol and other CNS depressant drugs. (ट्रायज़ोलम लेबल, चेतावनियां और सावधानियां)

CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (डाइफेनोक्सिलेट और एट्रोपिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam Co-administration of PREZISTA/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance… (डारुनाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam PREZCOBIX or PREZCOBIX PED is contraindicated in patients receiving certain co-administered drugs for which altered plasma… (डारुनाविर और कोबिसिस्टैट लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (नाल्मेफीन लेबल, चेतावनियां और सावधानियां)

…(selective blocker of Na v 1.8 sodium channels): suzetrigine • Opioid antagonists: naloxegol • PDE5 inhibitor: sildenafil (Revatio ® ) when used for pulmonary arterial hypertension (PAH) • Sedative/hypnotics: triazolam, oral midazolam • Serotonin receptor 1A agonist/serotonin receptor 2A antagonist: flibanserin • Vasopressin receptor antagonists: tolvaptan ➢ Drugs that… (निर्माट्रेल्विर और रिटोनाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Phenelzine sulfate should not be used in combination with dextromethorphan or with CNS depressants such as alcohol and certain narcotics. (फेनेलज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…Hypericum perforatum ) Lipid modifying agents: Lomitapide, lovastatin, simvastatin Non-nucleoside reverse transcriptase inhibitor: Delavirdine PDE5 inhibitor: Sildenafil (Revatio) (for treatment of pulmonary arterial hypertension) Sedative/hypnotics: Midazolam, triazolam Hypersensitivity to fosamprenavir calcium or amprenavir (e.g., Stevens-Johnson syndrome). (फोसएम्प्रेनाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

WARNING: PERSONNEL AND EQUIPMENT FOR MONITORING AND RESUSCITATION AND RISKS FROM CONCOMITANT USE WITH OPIOID ANALGESICS AND OTHER SEDATIVE-HYPNOTICS Personnel and Equipment for Monitoring and Resuscitation Only personnel trained in the administration of procedural sedation, and not involved in the conduct of the diagnostic or therapeutic procedure, should administer… (मिडाज़ोलम लेबल, बॉक्स्ड चेतावनी)

Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

If concomitant use with another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases. (मेटाक्सालोन लेबल, चेतावनियां और सावधानियां)

Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (मेटोलाज़ोन लेबल, चेतावनियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism… (रिटोनाविर लेबल, बॉक्स्ड चेतावनी)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (लेवोसेटिरिज़िन लेबल, चेतावनियां और सावधानियां)

…Non-opioid Analgesic (selective blocker of Nav1.8 sodium channels): suzetrigine PDE5 Inhibitor: sildenafil (Revatio ® ) when used for the treatment of pulmonary arterial hypertension Sedative/Hypnotics: triazolam, orally administered midazolam KALETRA is contraindicated with drugs that are potent CYP3A inducers where significantly reduced lopinavir plasma concentrations… (लोपिनाविर और रिटोनाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Caution patients receiving LOREEV XR against operating machinery or driving a motor vehicle as well to avoid the concomitant use of alcohol and other CNS depressant drugs during treatment ( 5.4 , 7 ) (लोराज़ेपाम लेबल, चेतावनियां और सावधानियां)

शराब को नींद लाने वाली दवाओं (ओपिओइड, बेंज़ोडायज़ेपिन, नींद की दवाएं, मसल रिलैक्सेंट) के साथ लेने से खतरनाक स्तर का उनींदापन, धीमी सांस और ओवरडोज़ हो सकता है। (NIAAA, Harmful Interactions: Mixing Alcohol with Medicines)

Table 8: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications ( 4.2 )]. (सिप्रोफ्लॉक्सासिन लेबल, दवाओं के इंटरैक्शन)

Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (सेटिरिज़िन लेबल, चेतावनियां और सावधानियां)

Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death [see Warnings and Precautions ( 5.2 )]. (सोडियम ऑक्सीबेट लेबल, बॉक्स्ड चेतावनी)

Rarely, cardiac arrests and death have been reported in association with the combined use of hydroxyzine hydrochloride intramuscularly and other CNS depressants. (हाइड्रॉक्सीज़िन लेबल, सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of Opioid Overdose after Opioid Discontinuation : Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

• Hyaluronidase should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs ( 7.2 ) (हायल्यूरोनिडेज़ लेबल, दवाओं के इंटरैक्शन)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of CALDOLOR with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 ) ]. (आइबुप्रोफेन लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (आइबुप्रोफेन और फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

There was also a slightly greater proportion of patients on NUVIGIL requiring new or increased use of antihypertensive medications (2.9%) compared to patients on placebo (1.8%). (आर्मोडाफिनिल लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Drug Interactions Other Antihypertensives: Indapamide may add to or potentiate the action of other antihypertensive drugs. (इंडापामाइड लेबल, दवाओं के इंटरैक्शन)

Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7 ) (इंडोमेथासिन लेबल, दवाओं के इंटरैक्शन)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

CYP2D6 Inhibitors : Concomitant use of paroxetine resulted in increased plasma levels of Lofexidine tablets. (लोफेक्सिडिन लेबल, दवाओं के इंटरैक्शन)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (एटेनोलोल लेबल, चेतावनियां)

Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (एटोमोक्सेटिन लेबल, दवाओं के इंटरैक्शन)

Epinephrine may antagonize the neuronal blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter. (एड्रेनालिन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (एपोएटिन अल्फा लेबल, चेतावनियां और सावधानियां)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (एपोप्रोस्टेनोल लेबल, दवाओं के इंटरैक्शन)

The administration of other potassium-sparing antihypertensives with NSAIDs has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function. (एप्लेरेनोन लेबल, दवाओं के इंटरैक्शन)

CYP2D6 Inhibitors : Concomitant use of paroxetine resulted in increased plasma levels of Lofexidine tablets. (लोफेक्सिडिन लेबल, दवाओं के इंटरैक्शन)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (एमिनोफाइलिन लेबल, दवाओं के इंटरैक्शन)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (एलोप्यूरिनॉल लेबल, चेतावनियां और सावधानियां)

Oral Naltrexone : Concomitant use may reduce efficacy of oral naltrexone. (लोफेक्सिडिन लेबल, दवाओं के इंटरैक्शन)

CYP2D6 Inhibitors : Concomitant use of paroxetine resulted in increased plasma levels of Lofexidine tablets. (लोफेक्सिडिन लेबल, दवाओं के इंटरैक्शन)

• Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (एवानाफिल लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. (एस्मोलोल लेबल, दवाओं के इंटरैक्शन)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of OXAPROZIN CAPSULES with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see WARNINGS AND PRECAUTIONS (5.6) ]. (ऑक्साप्रोज़िन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (कार्बिडोपा लेबल, दवाओं के इंटरैक्शन)

Antihypertensive drugs: May cause symptomatic postural hypotension. (कार्बिडोपा और लेवोडोपा लेबल, दवाओं के इंटरैक्शन)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (कार्बिडोपा, लेवोडोपा और एंटाकैपोन लेबल, दवाओं के इंटरैक्शन)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (कार्वेडिलोल लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (क्लोरथैलिडोन लेबल, दवाओं के इंटरैक्शन)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Thiazides may add to or potentiate the action of other antihypertensive drugs. (क्लोरोथायज़ाइड लेबल, चेतावनियां)

The thiazide component of quinapril and hydrochlorothiazide tablets may potentiate the action of other antihypertensive drugs, especially ganglionic or peripheral adrenergic- blocking drugs. (क्विनाप्रिल और हाइड्रोक्लोरोथायज़ाइड लेबल, चेतावनियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

CYP2D6 Inhibitors : Concomitant use of paroxetine resulted in increased plasma levels of Lofexidine tablets. (लोफेक्सिडिन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension (5.3). (टेराज़ोसिन लेबल, चेतावनियां और सावधानियां)

In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (टेस्टोस्टेरोन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

The recent use of other drugs that cause CNS depression or EPS symptoms may also increase the risk; consider reducing the dosage or discontinuing the drug. (ट्राइमेथोबेंज़ामाइड लेबल, चेतावनियां और सावधानियां)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Thiazides may add to or potentiate the action of other antihypertensive drugs. (ट्रायमटेरिन और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Excessive reduction of blood glucose (additive effect) f CNS depressant agents (including opioids, alcohol, sedatives, hypnotics) Use with caution d Increased CNS depression Dietary supplements containing sympathomimetics Contraindicated a Antidepressants including but not limited to: Other MAOIs (e.g., linezolid, intravenous methylene blue, selective MAOIs)… (ट्रैनिलसाइप्रोमिन लेबल, दवाओं के इंटरैक्शन)

The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (डाइएथिलप्रोपियॉन लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of ZIPSOR with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 ) ]. (डाइक्लोफेनाक लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of diclofenac sodium/misoprostol with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions (5.7) ] . (डाइक्लोफेनाक और मिसोप्रोस्टोल लेबल, दवाओं के इंटरैक्शन)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

CYP2D6 Inhibitors : Concomitant use of paroxetine resulted in increased plasma levels of Lofexidine tablets. (लोफेक्सिडिन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

• Antihypertensive Drugs: Monitor blood pressure. (डेक्समिथाइलफेनिडेट लेबल, दवाओं के इंटरैक्शन)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

CYP2D6 Inhibitors : Concomitant use of paroxetine resulted in increased plasma levels of Lofexidine tablets. (लोफेक्सिडिन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (थियोफाइलिन लेबल, दवाओं के इंटरैक्शन)

Antihypertensives: Possible additive hypotensive effects. (नाइट्रोग्लिसरीन लेबल, दवाओं के इंटरैक्शन)

Oral Naltrexone : Concomitant use may reduce efficacy of oral naltrexone. (लोफेक्सिडिन लेबल, दवाओं के इंटरैक्शन)

Oral Naltrexone : Concomitant use may reduce efficacy of oral naltrexone. (लोफेक्सिडिन लेबल, दवाओं के इंटरैक्शन)

Oral Naltrexone : Concomitant use may reduce efficacy of oral naltrexone. (लोफेक्सिडिन लेबल, दवाओं के इंटरैक्शन)

Oral Naltrexone : Concomitant use may reduce efficacy of oral naltrexone. (लोफेक्सिडिन लेबल, दवाओं के इंटरैक्शन)

Oral Naltrexone : Concomitant use may reduce efficacy of oral naltrexone. (लोफेक्सिडिन लेबल, दवाओं के इंटरैक्शन)

Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (निमोडिपिन लेबल, दवाओं के इंटरैक्शन)

Antihypertensive Therapy Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension. (नियासिन लेबल, दवाओं के इंटरैक्शन)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

( 5.3 Hepatotoxicity) Hypertension: Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (नेप्रोक्सेन लेबल, चेतावनियां और सावधानियां)

Intervention : During concomitant use of naproxen and esomeprazole magnesium delayed-release tablets with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions (5.6) ]. (नेप्रोक्सेन और एसोमेप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (पाइरोक्सिकैम लेबल, दवाओं के इंटरैक्शन)

Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (पाज़ोपैनिब लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (पेंटोक्सिफाइलिन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (पैरासिटामोल और आइबुप्रोफेन लेबल, चेतावनियां और सावधानियां)

CYP2D6 Inhibitors : Concomitant use of paroxetine resulted in increased plasma levels of Lofexidine tablets. (लोफेक्सिडिन लेबल, दवाओं के इंटरैक्शन)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of prazosin hydrochloride capsules. (प्राज़ोसिन लेबल, चेतावनियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

CYP2D6 Inhibitors : Concomitant use of paroxetine resulted in increased plasma levels of Lofexidine tablets. (लोफेक्सिडिन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of FENOPROFEN CALCIUM with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 ) ]. (फेनोप्रोफेन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

The thiazide component of fosinopril sodium and hydrochlorothiazide may potentiate the action of other antihypertensive drugs, especially ganglionic or peripheral adrenergic-blocking drugs. (फोसिनोप्रिल और हाइड्रोक्लोरोथायज़ाइड लेबल, चेतावनियां)

Monitor for changes in blood pressure and adjust the dose of other antihypertensive drugs if needed. (फ्यूरोसेमाइड लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of flurbiprofen with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions (5) ]. (फ्लर्बिप्रोफेन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Triazolam/flurazepam: Coadministration of buspirone with either triazolam or flurazepam did not appear to prolong or intensify the sedative effects of either benzodiazepine. (बस्पिरोन लेबल, दवाओं के इंटरैक्शन)

Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use caution when midazolam or triazolam is concomitantly administered with BIXLENVO. (बिक्टेग्राविर, एमट्रिसिटाबिन और टेनोफोविर एलाफेनामाइड लेबल, दवाओं के इंटरैक्शन)

Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (बिसोप्रोलोल लेबल, चेतावनियां)

Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (बिसोप्रोलोल और हाइड्रोक्लोरोथायज़ाइड लेबल, चेतावनियां)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (बुमेटेनाइड लेबल, दवाओं के इंटरैक्शन)

Amphetamines may decrease the hypotensive effect of antihypertensives. (बेंज़फेटामाइन लेबल, दवाओं के इंटरैक्शन)

The thiazide component of Lotensin HCT may potentiate the action of other antihypertensive drugs, especially ganglionic or peripheral adrenergic-blocking drugs. (बेनाज़ेप्रिल और हाइड्रोक्लोरोथायज़ाइड लेबल, चेतावनियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (बोर्टेज़ोमिब लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (ब्यूपिवाकेन लेबल, चेतावनियां और सावधानियां)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (ब्यूपिवाकेन और एड्रेनालिन लेबल, चेतावनियां और सावधानियां)

CYP2D6 Inhibitors : Concomitant use of paroxetine resulted in increased plasma levels of Lofexidine tablets. (लोफेक्सिडिन लेबल, दवाओं के इंटरैक्शन)

Use with CNS depressants may result in an additive or potentiating effect. (ब्रिमोनिडिन लेबल, दवाओं के इंटरैक्शन)

Use with CNS depressants may result in an additive or potentiating effect. (ब्रिमोनिडिन और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Use caution in patients taking antihypertensive medications. (ब्रोमोक्रिप्टिन लेबल, चेतावनियां और सावधानियां)

Oral Naltrexone : Concomitant use may reduce efficacy of oral naltrexone. (लोफेक्सिडिन लेबल, दवाओं के इंटरैक्शन)

Antihypertensive Drugs: Monitor blood pressure. (मिथाइलफेनिडेट लेबल, दवाओं के इंटरैक्शन)

CYP2D6 Inhibitors : Concomitant use of paroxetine resulted in increased plasma levels of Lofexidine tablets. (लोफेक्सिडिन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

The action of Mecamylamine HCl may be potentiated by anesthesia, other antihypertensive drugs and alcohol. (मेकामाइलामिन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (मेटाइरोसिन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of mefenamic acid with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.6 )] . (मेफेनामिक एसिड लेबल, दवाओं के इंटरैक्शन)

Intervention: During concomitant use of QAMZOVA with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 ) ]. (मेलोक्सिकैम लेबल, दवाओं के इंटरैक्शन)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

However, a retrospective analysis of the use of antihypertensive medication in these studies showed that a greater proportion of patients on PROVIGIL required new or increased use of antihypertensive medications (2.4%) compared to patients on placebo (0.7%). (मोडाफिनिल लेबल, चेतावनियां और सावधानियां)

Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (रियोसिगुआट लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

CYP2D6 Inhibitors : Concomitant use of paroxetine resulted in increased plasma levels of Lofexidine tablets. (लोफेक्सिडिन लेबल, दवाओं के इंटरैक्शन)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (लिडोकेन और एड्रेनालिन लेबल, चेतावनियां और सावधानियां)

When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed (see DOSAGE AND ADMINISTRATION ). (लिसिनोप्रिल और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

If hypertension persists, the dose of Neoral should be further reduced or blood pressure should be controlled with antihypertensive agents. (साइक्लोस्पोरिन लेबल, सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

CYP2D6 Inhibitors : Concomitant use of paroxetine resulted in increased plasma levels of Lofexidine tablets. (लोफेक्सिडिन लेबल, दवाओं के इंटरैक्शन)

CYP2D6 Inhibitors : Concomitant use of paroxetine resulted in increased plasma levels of Lofexidine tablets. (लोफेक्सिडिन लेबल, दवाओं के इंटरैक्शन)

However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (सिलोडोसिन लेबल, चेतावनियां और सावधानियां)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (सिल्डेनाफिल लेबल, चेतावनियां और सावधानियां)

Initiate and/or adjust antihypertensive therapy as appropriate. (सुनिटिनिब लेबल, चेतावनियां और सावधानियां)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (सुमाट्रिप्टान और नेप्रोक्सेन लेबल, दवाओं के इंटरैक्शन)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Intervention: During concomitant use of VYSCOXA with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions (5.6) ]. (सेलेकॉक्सिब लेबल, दवाओं के इंटरैक्शन)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (सोराफेनिब लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Thiazides may add to or potentiate the action of other antihypertensive drugs. (स्पिरोनोलैक्टोन और हाइड्रोक्लोरोथायज़ाइड लेबल, चेतावनियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (इकाटिबेंट लेबल, दवाओं के इंटरैक्शन)

In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect. (इसराडिपिन लेबल, दवाओं के इंटरैक्शन)

Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (एटोडोलैक लेबल, दवाओं के इंटरैक्शन)

Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (एनालाप्रिल और हाइड्रोक्लोरोथायज़ाइड लेबल, चेतावनियां)

Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (एफेड्रिन लेबल, दवाओं के इंटरैक्शन)

Alpha-adrenergic agonists as a class may impact blood pressure. (ऑक्सीमेटाज़ोलिन लेबल, चेतावनियां और सावधानियां)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (कीटोप्रोफेन लेबल, चेतावनियां और सावधानियां)

Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors and/or angiotensin II receptor antagonists. (कीटोरोलैक लेबल, दवाओं के इंटरैक्शन)

Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (कैंडेसार्टन और हाइड्रोक्लोरोथायज़ाइड लेबल, चेतावनियां)

Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (कैप्टोप्रिल लेबल, चेतावनियां)

Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (क्विनाप्रिल लेबल, चेतावनियां)

DRUG INTERACTIONS ACE Inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE Inhibitors. (टोल्मेटिन लेबल, दवाओं के इंटरैक्शन)

Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (ट्रैंडोलाप्रिल लेबल, चेतावनियां)

Drug Interactions ACE-inhibitors and Angiotensin II Anagonists Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors and angiotensin II antagonists. (डाइफ्लुनिसाल लेबल, दवाओं के इंटरैक्शन)

Antihistamines Amphetamines may counteract the sedative effect of antihistamines. (डेक्सट्रोएम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (डेसोजेस्ट्रेल और एथिनिल एस्ट्राडियोल लेबल, चेतावनियां)

In Drug-Induced CNS and Respiratory Depression Doxapram alone may not stimulate adequate spontaneous breathing or provide sufficient arousal in patients who are severely depressed either due to respiratory failure or to CNS depressant drugs, but may be used as an adjunct to established supportive measures and resuscitative techniques. (डॉक्साप्राम लेबल, चेतावनियां)

Hypertensive patients, and patients concomitantly receiving other antihypertensive medications, may be more sensitive to the effects of sodium nitroprusside than normal subjects. (नाइट्रोप्रुसाइड लेबल, चेतावनियां)

The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy. (निसोल्डिपिन लेबल, दवाओं के इंटरैक्शन)

Drug Interactions: ACE-inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (नैबुमेटोन लेबल, दवाओं के इंटरैक्शन)

Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (फोसिनोप्रिल लेबल, चेतावनियां)

Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (मिथाइलडोपा लेबल, दवाओं के इंटरैक्शन)

In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (मेक्सिलेटिन लेबल, दवाओं के इंटरैक्शन)

Because of its relative beta 1 cardio-selectivity, however, Metoprolol Tartrate Tablets may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (मेटोप्रोलोल लेबल, चेतावनियां और सावधानियां)

Because of its relative beta 1 cardio-selectivity, however, metoprolol tartrate may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (मेटोप्रोलोल और हाइड्रोक्लोरोथायज़ाइड लेबल, चेतावनियां और सावधानियां)

Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (मोएक्सिप्रिल लेबल, चेतावनियां)

DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (साल्सालेट लेबल, दवाओं के इंटरैक्शन)

Drug Interactions ACE-Inhibitors and Angiotensin II Antagonists Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors and angiotensin II antagonists. (सुलिंडैक लेबल, दवाओं के इंटरैक्शन)

When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. (हाइड्रालाज़िन लेबल, दवाओं के इंटरैक्शन)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (मोंटेलुकास्ट लेबल, दवाओं के इंटरैक्शन)

Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use with caution when midazolam or triazolam is concomitantly administered with SUNLENCA 7.4 Drugs without Clinically Significant Interactions with SUNLENCA Based on drug interaction studies conducted with SUNLENCA, no clinically significant drug interactions have been observed with:… (लेनाकैपाविर लेबल, दवाओं के इंटरैक्शन)